News | April 07, 2024
Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Acquisition of exclusive commercialization rights for European markets
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Beneficiaries can create Ayushman Card from their mobile phone using Ayushman App which has been downloaded 52 lakh times since its launch on 13th September, 2023
The company has received five final approvals
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Phase 3 data expected in the second half of 2024
Subscribe To Our Newsletter & Stay Updated
